Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 21, 2024

BUY
$7.21 - $10.68 $2,638 - $3,908
366 Added 95.56%
749 $5,000
Q3 2023

Oct 30, 2023

BUY
$7.21 - $10.68 $2,638 - $3,908
366 Added 95.56%
749 $6,000
Q2 2023

May 21, 2024

BUY
$6.49 - $13.36 $162 - $334
25 Added 6.98%
383 $3,000
Q2 2023

Jul 27, 2023

BUY
$6.49 - $13.36 $162 - $334
25 Added 6.98%
383 $4,000
Q1 2023

May 21, 2024

BUY
$3.78 - $10.38 $340 - $934
90 Added 33.58%
358 $3,000
Q1 2023

Apr 27, 2023

BUY
$3.78 - $10.38 $340 - $934
90 Added 33.58%
358 $3,000
Q4 2022

May 21, 2024

BUY
$4.09 - $15.0 $1,096 - $4,020
268 New
268 $1,000
Q4 2022

Jan 31, 2023

BUY
$4.09 - $15.0 $85 - $315
21 Added 8.5%
268 $1,000
Q3 2022

Oct 21, 2022

BUY
$5.0 - $14.32 $1,235 - $3,537
247 New
247 $4,000

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $70.2M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.